Objective: The GUARD study evaluated the effectiveness, safety, and tolerability of
vildagliptin treatment with or without metformin in patients with type 2 diabetes mellitus …

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels
in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple …

Currently, the prevalence of type 2 diabetes mellitus (DM2) progressively increases. Along
with the progression of diabetes mellitus, need for insulin inevitably arises in connection with …

Blood pressure and lipid profile are important determinants of cardiovascular risk in patients
with type 2 diabetes mellitus (T2DM). To identify the pleiotropic effects of vildagliptin other …

Background The use of fixed dose combination oral antidiabetic drugs (OADs) in the
therapeutic management of type 2 diabetes mellitus (DM) patients is becoming popular …

INTRODUCTION. The aim of this study was to assess the efficacy and safety of vildagliptin in
subjects not achieving satisfactory glycemic control while on two oral antihyperglycemic …

OBJECTIVE: The aim is to assess the comparative efficacy and safety of combination
therapy with vildagliptin and metformin vs. metformin monotherapy in the treatment of type 2 …

AIM: To investigate efficacy and safety of vildagliptin compared to other oral antidiabetics in
clinical practice in Germany. METHODS: In this prospective, open, observational study …

Aim In this post hoc analysis of the EDGE study, we assessed the effectiveness and safety of
vildagliptin versus other oral antidiabetes drugs (OADs) as add-on to first-line sulphonylurea …